Pelthos Therapeutics reports Q2 2026 revenue growth on Zelsuvmi demand
Pelthos Therapeutics said second-quarter 2026 net product revenue rose to $15.4 million from $10.7 million in Q1, as Zelsuvmi prescription units increased 48% to 11,925.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pelthos Therapeutics reports second-quarter 2026 financial results
Pelthos Therapeutics (PTHS) announces its second-quarter 2026 financial results, with no EPS, revenue, or guidance figures provided in the feed.